Neumora Therapeutics Inc.’s shares plummeted after the company’s experimental drug failed to show a benefit in a final-stage ...

Neumora Therapeutics Inc.’s stock tumbled 81% Thursday after the clinical-stage biotech said a late-stage trial of a ...

Neumora Therapeutics ( NMRA) shares crashed 80% to an all-time low Thursday when the biopharmaceutical firm announced that a ...

Neumora Therapeutics shares plunged more than 80% on Thursday after its lead drug candidate failed to help patients with ...

Patients who received the drug, called navacaprant, showed no more improvement in depressive symptoms than people who ...

Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...

The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...

Neumora Therapeutics Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -74.98%. The profit margin, also known as the revenue ratio or gross profit ...

Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) saw some unusual options trading on Monday. Stock traders acquired ...

Neumora Therapeutics (NMRA) crashed after its Phase 3 study for its lead asset navacaprant in major depressive disorder ...

Neumora Therapeutics’ big bet on a new era of neuroscience has delivered an age-old result. The first of three late-stage ...

Neumora Therapeutics stock collapsed Thursday after its experimental depression treatment failed in the first of three ...